Cargando…

Hypokalemia Events With Sodium Zirconium Cyclosilicate and Placebo in Hemodialysis Patients

Detalles Bibliográficos
Autores principales:	Fishbane, Steven, Ford, Martin, Fukagawa, Masafumi, McCafferty, Kieran, Rastogi, Anjay, Spinowitz, Bruce, Staroselskiy, Konstantin, Vishnevskiy, Konstantin, Lisovskaja, Vera, Al-Shurbaji, Ayman, Guzman, Nicolas, Bhandari, Sunil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039482/ https://www.ncbi.nlm.nih.gov/pubmed/35497779 http://dx.doi.org/10.1016/j.ekir.2022.01.1058

Ejemplares similares

Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE
por: Fishbane, Steven, et al.
Publicado: (2022)

Dose effect analysis of sodium zirconium cyclosilicate in hemodialysis patients
por: Spinowitz, Bruce, et al.
Publicado: (2021)

Effectiveness of Sodium Zirconium Cyclosilicate in Hemodialysis Patients With Severe Hyperkalemia
por: Ford, Martin, et al.
Publicado: (2021)

Course of Hyperkalemia in Patients on Hemodialysis
por: Spinowitz, Bruce, et al.
Publicado: (2022)

Evaluation of the effect of sodium zirconium cyclosilicate on arrhythmia-related cardiovascular outcomes in patients receiving chronic haemodialysis with hyperkalaemia: protocol for the multicentre, randomised, controlled DIALIZE-Outcomes study
por: Fishbane, Steven, et al.
Publicado: (2023)

A Phase 1, open-label, crossover study evaluating the effect of a single dose of sodium zirconium cyclosilicate on the pharmacokinetics of tacrolimus and cyclosporin
por: Någård, Mats, et al.
Publicado: (2022)

Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure
por: Tardif, Jean‐Claude, et al.
Publicado: (2022)

Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials
por: Roger, Simon D, et al.
Publicado: (2020)

Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
por: Hoy, Sheridan M.
Publicado: (2018)

Erratum to: Sodium Zirconium Cyclosilicate Increases Serum Bicarbonate Concentrations Among Patients with Hyperkalaemia: Exploratory Analyses from Three Randomized, Multi-Dose, Placebo-Controlled Trials
por: Roger, Simon D, et al.
Publicado: (2020)

Correction to: Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
por: Hoy, Sheridan M.
Publicado: (2019)

Letter to the editor regarding ‘‘Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-analysis: Patiromer and Sodium Zirconium Cyclosilicate in Hyperkalemia’
por: Zarzuela, Donna, et al.
Publicado: (2021)

Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double‐blind, Placebo‐controlled Study (ENERGIZE)
por: Peacock, W. Frank, et al.
Publicado: (2020)

Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
por: Rosano, Giuseppe M C, et al.
Publicado: (2019)

Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis
por: Shrestha, Dhan Bahadur, et al.
Publicado: (2021)

Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study
por: Roger, Simon D, et al.
Publicado: (2020)

Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate
por: Oshima, Akira, et al.
Publicado: (2021)

Impact of Sodium Zirconium Cyclosilicate Therapy on Nutrition Status in Patients with Hyperkalemia
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Impact of Sodium Zirconium Cyclosilicate Therapy Cessation in Patients with Systolic Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Risk Factors for Rapid Recurrence of Hyperkalemia following Cessation of Sodium Zirconium Cyclosilicate
por: Imamura, Teruhiko, et al.
Publicado: (2022)

A Real-World Experience of Hyperkalemia Management Using Sodium Zirconium Cyclosilicate in Chronic Hemodialysis: A Multicenter Clinical Audit
por: Qu, XiaoJie, et al.
Publicado: (2023)

Association of Hyperkalemia and Hypokalemia with Patient Characteristics and Clinical Outcomes in Japanese Hemodialysis (HD) Patients
por: Iwagami, Masao, et al.
Publicado: (2023)

Clinical Implications of Sodium Zirconium Cyclosilicate Therapy in Patients with Systolic Heart Failure and Hyperkalemia
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden
por: Kim, Kun, et al.
Publicado: (2022)

Phase I Study of the Pharmacodynamics and Safety of Sodium Zirconium Cyclosilicate in Healthy Chinese Adults
por: Cheung, Tommy, et al.
Publicado: (2022)

Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo‐controlled HARMONIZE‐Global study
por: Zannad, Faiez, et al.
Publicado: (2020)

Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program
por: Fishbane, Steven, et al.
Publicado: (2022)

Effects of sodium zirconium cyclosilicate on sodium and potassium excretion in healthy adults: a Phase 1 study
por: Någård, Mats, et al.
Publicado: (2020)

Successful Conversion from Conventional Potassium Binder to Sodium Zirconium Cyclosilicate in a Patient with Refractory Constipation
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Compared effectiveness of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on hyperkalemia in patients with chronic kidney disease
por: Nakayama, Takashin, et al.
Publicado: (2023)

Sodium zirconium cyclosilicate pretreatment for formula in vitro reduces potassium intake in infants with chronic kidney disease
por: Liu, Boxuan, et al.
Publicado: (2022)

Medical Costs in Patients with Hyperkalemia on Long-Term Sodium Zirconium Cyclosilicate Therapy: The RECOGNIZE II Study
por: Agiro, Abiy, et al.
Publicado: (2023)

Sodium zirconium cyclosilicate (ZS-9) treatment in patients with serum potassium >6.5 mEq/L
por: Rasmussen, Henrik
Publicado: (2015)

Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review
por: Beccari, Mario V, et al.
Publicado: (2017)

Combination Therapy Using Sodium Zirconium Cyclosilicate and a Mineralocorticoid Receptor Antagonist in Patients with Heart Failure and Hyperkalemia
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review [Erratum]
Publicado: (2019)

Constipation as a Drug-Related Adverse Effect in Patients with Hyperkalemia: Sodium Zirconium Cyclosilicate versus Conventional Potassium Binders
por: Hida, Yuki, et al.
Publicado: (2023)

Evaluation of safety, effectiveness and treatment patterns of sodium zirconium cyclosilicate in management of hyperkalaemia in China: a real-world study protocol
por: Shen, Nan, et al.
Publicado: (2023)

Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose–response, phase 2/3 study
por: Kashihara, Naoki, et al.
Publicado: (2020)

Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis
por: Zhang, Yaru, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v4p8hl8jfbcl2deb93q5qg8itp